Trial Profile
Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Anti GD2 chimeric antigen receptor T cell therapy Bellicum Pharmaceuticals (Primary) ; Cyclophosphamide; Rimiducid
- Indications Malignant melanoma; Neuroblastoma; Osteosarcoma; Solid tumours
- Focus Adverse reactions
- 19 Apr 2023 Results assessing Immune determinants of CAR-T expansion in solid tumor patients receiving GD2 CAR-T cell therapy presented at the 114th Annual Meeting of the American Association for Cancer Research
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
- 01 Feb 2017 Status changed from recruiting to completed.